LNTH Lantheus Holdings, Inc.
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1521036 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2.4%
TTM net income YoY61.0%
TTM EPS YoY66.8%
Revenue 3-yr CAGR9.0%
Net income 3-yr CAGR37.4%
Margins
Gross margin61.3%
Operating margin18.6%
Net margin17.3%
FCF margin25.2%
EBITDA margin24.4%
Returns
ROE21.8%
ROA11.4%
ROIC (approx.)18.0%
Asset turnover0.66x
Leverage & solvency
Liabilities / assets44.8%
Debt / equity0.42x
Current ratio3.25x
Interest coverage14.70x
Cash quality & payout
Operating cash flow / net income1.52x
Accruals ratio-5.9%
Payout ratio—
Capex / revenue1.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $389.91M | $388.18M | $377.33M | $406.79M | $384.01M | $378.05M | $372.76M | $391.11M |
| Cost of revenue | $146.50M | $146.32M | $146.41M | $165.91M | $161.65M | $137.03M | $135.06M | $142.56M |
| Gross profit | $243.41M | $241.85M | $230.92M | $240.88M | $222.37M | $241.01M | $237.70M | $248.54M |
| R&D expense | $92.76M | $38.20M | $39.38M | $47.48M | $48.02M | $45.49M | $36.31M | $35.33M |
| SG&A expense | $70.38M | $20.63M | $57.53M | $69.89M | $81.90M | $66.52M | $56.82M | $57.87M |
| Operating income | $32.21M | $100.22M | $81.33M | $77.18M | $43.62M | $87.97M | $102.07M | $113.87M |
| Interest expense | $4.94M | $4.92M | $4.86M | $5.08M | $4.95M | $4.92M | $4.80M | $5.04M |
| Pretax income | $21.78M | $93.83M | $156.41M | $70.36M | $42.38M | $104.52M | $96.53M | -$783,000 |
| Income tax | -$594,000 | $18.80M | $37.99M | $16.28M | $14.61M | $25.76M | $23.58M | $11.01M |
| Net income | $22.37M | $75.03M | $118.42M | $54.09M | $27.77M | $78.75M | $72.94M | -$11.79M |
| EBITDA | $55.10M | $122.80M | $104.01M | $100.02M | $64.02M | $101.20M | $115.69M | $131.16M |
| EPS (basic) | 0.34 | 1.15 | 1.83 | — | 0.41 | 1.15 | 1.06 | — |
| EPS (diluted) | 0.33 | 1.11 | 1.80 | — | 0.41 | 1.12 | 1.02 | — |
| Weighted avg. shares (diluted) | 68.41M | 67.52M | 65.77M | — | 67.66M | 70.31M | 71.46M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $683.61M | $593.30M | $595.01M | $359.12M | $382.01M | $695.57M | $697.26M | $914.49M |
| Receivables | $345.68M | $352.89M | $355.67M | $358.64M | $351.38M | $336.58M | $348.75M | $321.26M |
| Inventory | $64.21M | $57.55M | $61.34M | $64.67M | $62.04M | $62.16M | $69.13M | $68.03M |
| Current assets | $1.12B | $1.03B | $942.29M | $899.96M | $925.09M | $1.20B | $1.42B | $1.33B |
| PP&E, net | $149.63M | $153.27M | $157.56M | $163.69M | $164.07M | $157.73M | $180.78M | $176.80M |
| Goodwill | $238.63M | $239.05M | $239.40M | $239.52M | $240.33M | $176.87M | $61.19M | $61.19M |
| Intangibles | $641.61M | $689.34M | $706.06M | $722.78M | $739.26M | $359.95M | $153.75M | $161.76M |
| Total assets | $2.46B | $2.41B | $2.35B | $2.23B | $2.28B | $2.12B | $2.06B | $1.98B |
| Current liabilities | $345.97M | $335.68M | $333.17M | $333.42M | $346.84M | $280.13M | $248.00M | $240.53M |
| Short-term debt | $605,000 | $697,000 | $803,000 | $738,000 | $871,000 | $796,000 | $747,000 | $974,000 |
| Long-term debt | $571.14M | $570.35M | $569.60M | $568.68M | $567.94M | $566.85M | $566.10M | $565.28M |
| Total debt | $571.74M | $571.05M | $570.41M | $569.42M | $568.81M | $567.64M | $566.85M | $566.25M |
| Total liabilities | $1.10B | $1.10B | $1.13B | $1.14B | $1.16B | $949.29M | $891.03M | $892.33M |
| Shareholders' equity | $1.36B | $1.31B | $1.21B | $1.09B | $1.12B | $1.17B | $1.16B | $1.09B |
| Net debt | -$111.87M | -$22.25M | -$24.61M | $210.29M | $186.80M | -$127.93M | -$130.42M | -$348.23M |
| Shares outstanding | 65.37M | 65.27M | 65.07M | 64.59M | 71.77M | 71.70M | 71.61M | 68.45M |
| Cash flow statement | ||||||||
| Operating cash flow | $101.97M | $92.20M | $125.13M | $90.18M | $105.29M | $87.11M | $107.56M | $157.73M |
| Capital expenditure | $2.05M | $2.33M | $3.23M | $8.79M | $10.62M | $7.96M | $8.72M | $16.37M |
| Free cash flow | $99.93M | $89.87M | $121.90M | $81.39M | $94.67M | $79.14M | $98.84M | $141.36M |
| Investing cash flow | -$11.13M | -$2.02M | $25.99M | -$11.51M | -$319.47M | -$232.47M | -$63.72M | -$6.60M |
| Financing cash flow | -$460,000 | $4.50M | -$11.62M | -$100.79M | -$99.17M | -$98.41M | -$18.22M | -$103.66M |
| Depreciation & amortization | $22.90M | $22.58M | $22.68M | $22.83M | $20.41M | $13.23M | $13.63M | $17.29M |
| Stock-based compensation | $21.88M | $20.01M | $16.04M | $17.54M | $24.50M | $22.32M | $21.20M | $22.16M |
| Share buybacks | $0 | — | — | $100.02M | $100.00M | — | — | $100.00M |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.